Patents by Inventor Keli Hippen

Keli Hippen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MATERIALS AND METHODS FOR MODIFYING THE ACTIVITY OF T CELLS
    Publication number: 20220348870
    Abstract: This disclosure provides miRNA/mRNA pairs that can be used to increase the efficacy of T cells or to down-modulate T cell efficacy and restore equilibrium.
    Type: Application
    Filed: July 13, 2022
    Publication date: November 3, 2022
    Inventors: Bruce R. Blazar, Keli Hippen, Pavan Reddy, Yaping Sun, Ramiro Garzon
  • Materials and methods for modifying the activity of T cells
    Patent number: 11390848
    Abstract: This disclosure provides miRNA/mRNA pairs that can be used to increase the efficacy of T cells or to down-modulate T cell efficacy and restore equilibrium.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: July 19, 2022
    Assignees: Regents of the University of Minnesota, Regents of the University of Michigan, The Ohio State University
    Inventors: Bruce R. Blazar, Keli Hippen, Pavan Reddy, Yaping Sun, Ramiro Garzon
  • METHODS AND COMPOSITIONS FOR INCREASING THE SUPPRESSIVE FUNCTION OF REGULATORY T-CELLS (TREGS)
    Publication number: 20210322455
    Abstract: Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs) are provided.
    Type: Application
    Filed: April 23, 2021
    Publication date: October 21, 2021
    Inventors: Bruce R. Blazar, Cameron McDonald-Hyman, Michael Dustin, Sudha Kumari, Tom Neubert, James Muller, Keli Hippen
  • INDUCIBLE REGULATORY T-CELL GENERATION FOR HEMATOPOIETIC TRANSPLANTS
    Publication number: 20210275650
    Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
    Type: Application
    Filed: December 24, 2020
    Publication date: September 9, 2021
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Drug-Resistant Immune Cells and Methods of Use Thereof
    Publication number: 20210213062
    Abstract: The present disclosure provides modified cells including pluripotent stem cells, hematopoietic precursor cells, and hematopoietic cells (e.g., modified Tregs) that are steroid and/or calcineurin inhibitor-resistant. The present disclosure provides methods for generating steroid and/or calcineurin inhibitor-resistant modified cells including pluripotent stem cells, hematopoietic precursor cells, and hematopoietic cells. Also provided herein are compositions and methods of treatment.
    Type: Application
    Filed: May 16, 2019
    Publication date: July 15, 2021
    Inventors: Mark J. Osborn, Keli Hippen, Bruce R. Blazer
  • Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs)
    Patent number: 10993959
    Abstract: Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs) are provided.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: May 4, 2021
    Assignees: Regents of the University of Minnesota, New York University
    Inventors: Bruce R. Blazar, Cameron McDonald-Hyman, Michael Dustin, Sudha Kumari, Tom Neubert, James Muller, Keli Hippen
  • Inducible regulatory t-cell generation for hematopoietic transplants
    Patent number: 10874727
    Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: December 29, 2020
    Assignees: The Trustees of the University of Pennsylvania, Regents of the University of Minnesota
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Methods to Expand a T Regulatory Cell Master Cell Bank
    Publication number: 20200263131
    Abstract: The present invention provides compositions and methods for expanding natural T regulatory cells (nTregs) without substantially sacrificing suppressive function of the cells. Accordingly, the invention provides uses of the expanded nTregs for cellular therapy.
    Type: Application
    Filed: March 27, 2019
    Publication date: August 20, 2020
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • MATERIALS AND METHODS FOR MODIFYING THE ACTIVITY OF T CELLS
    Publication number: 20190203173
    Abstract: This disclosure provides miRNA/mRNA pairs that can be used to increase the efficacy of T cells or to down-modulate T cell efficacy and restore equilibrium.
    Type: Application
    Filed: June 28, 2017
    Publication date: July 4, 2019
    Applicant: Regents of the University of Minnesota
    Inventors: Bruce R. Blazar, Keli Hippen, Pavan Reddy, Yaping Sun, Ramiro Garzon
  • INDUCIBLE REGULATORY T-CELL GENERATION FOR HEMATOPOIETIC TRANSPLANTS
    Publication number: 20190022199
    Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
    Type: Application
    Filed: June 20, 2018
    Publication date: January 24, 2019
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • METHODS AND COMPOSITIONS FOR INCREASING THE SUPPRESSIVE FUNCTION OF REGULATORY T-CELLS (TREGS)
    Publication number: 20190022125
    Abstract: Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs) are provided.
    Type: Application
    Filed: September 2, 2016
    Publication date: January 24, 2019
    Inventors: Bruce R. Blazar, Cameron McDonald-Hyman, Michael Dustin, Sudha Kumari, Tom Neubert, James Muller, Keli Hippen
  • INDUCIBLE REGULATORY T-CELL GENERATION FOR HEMATOPOIETIC TRANSPLANTS
    Publication number: 20160151471
    Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
    Type: Application
    Filed: December 10, 2015
    Publication date: June 2, 2016
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Inducible regulatory T-cell generation for hematopoietic transplants
    Patent number: 9228172
    Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: January 5, 2016
    Assignees: The Trustees of the University of Pennsylvania, Regents of the University of Minnesota
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Methods to Expand a T Regulatory Cell Master Cell Bank
    Publication number: 20130101567
    Abstract: Compositions and methods for expanding natural T regulatory cells (nTregs) without substantially sacrificing suppressive function of the cells are disclosed. Also provided are uses of the expanded nTregs for cellular therapy.
    Type: Application
    Filed: March 28, 2011
    Publication date: April 25, 2013
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Inducible Regulatory T-Cell Generation for Hematopoietic Transplants
    Publication number: 20110268752
    Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
    Type: Application
    Filed: June 19, 2009
    Publication date: November 3, 2011
    Applicants: The Trustees of The University of Pennsylvania, Regents of The University of Minnesota
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen